Cargando…

Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy

Myotonic dystrophy type 1 (DM1) is a rare neuromuscular disease caused by expansion of unstable CTG repeats in a non-coding region of the DMPK gene. CUG expansions in mutant DMPK transcripts sequester MBNL1 proteins in ribonuclear foci. Depletion of this protein is a primary contributor to disease s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cerro-Herreros, Estefanía, González-Martínez, Irene, Moreno, Nerea, Espinosa-Espinosa, Jorge, Fernández-Costa, Juan M., Colom-Rodrigo, Anna, Overby, Sarah J., Seoane-Miraz, David, Poyatos-García, Javier, Vilchez, Juan J., López de Munain, Adolfo, Varela, Miguel A., Wood, Matthew J., Pérez-Alonso, Manuel, Llamusí, Beatriz, Artero, Rubén
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413838/ https://www.ncbi.nlm.nih.gov/pubmed/34513303 http://dx.doi.org/10.1016/j.omtn.2021.07.017

Ejemplares similares

Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy
por: Cerro-Herreros, Estefanía, et al.
Publicado: (2020)

miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models
por: Cerro-Herreros, Estefania, et al.
Publicado: (2018)

Increased autophagy and apoptosis contribute to muscle atrophy in a myotonic dystrophy type 1 Drosophila model
por: Bargiela, Ariadna, et al.
Publicado: (2015)

Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression
por: González-Martínez, Irene, et al.
Publicado: (2023)

Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model
por: Overby, Sarah J., et al.
Publicado: (2022)

BlockmiR AONs as Site-Specific Therapeutic MBNL Modulation in Myotonic Dystrophy 2D and 3D Muscle Cells and HSA(LR) Mice
por: Overby, Sarah J., et al.
Publicado: (2023)

Derepressing muscleblind expression by miRNA sponges ameliorates myotonic dystrophy-like phenotypes in Drosophila
por: Cerro-Herreros, Estefania, et al.
Publicado: (2016)

AntagomiR-103 and -107 Treatment Affects Cardiac Function and Metabolism
por: Rech, Monika, et al.
Publicado: (2018)

Expanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis genes
por: Cerro-Herreros, Estefania, et al.
Publicado: (2017)

Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia
por: Dereani, Sara, et al.
Publicado: (2014)

Effects of AntagomiRs on Different Lung Diseases in Human, Cellular, and Animal Models
por: Murdaca, Giuseppe, et al.
Publicado: (2019)

AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm
por: Gangemi, Sebastiano, et al.
Publicado: (2021)

AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines
por: Kazemi, Azam, et al.
Publicado: (2021)

Targeting Leukemia Stem Cells in vivo with AntagomiR-126 Nanoparticles in Acute Myeloid Leukemia
por: Dorrance, Adrienne M., et al.
Publicado: (2015)

AntagomiR‐29b inhibits vascular and valvular calcification and improves heart function in rats
por: Fang, Ming, et al.
Publicado: (2020)

A novel biologically hierarchical hydrogel with osteoblast precursor‐targeting extracellular vesicles ameliorates bone loss in vivo via the sequential action of antagomiR‐200b‐3p and antagomiR‐130b‐3p
por: Dai, Hanhao, et al.
Publicado: (2023)

Two Enhancers Control Transcription of Drosophila muscleblind in the Embryonic Somatic Musculature and in the Central Nervous System
por: Bargiela, Ariadna, et al.
Publicado: (2014)

Exosomal Delivery of AntagomiRs Targeting Viral and Cellular MicroRNAs Synergistically Inhibits Cancer Angiogenesis
por: Wang, Jianguo, et al.
Publicado: (2020)

Musashi-2 contributes to myotonic dystrophy muscle dysfunction by promoting excessive autophagy through miR-7 biogenesis repression
por: Sabater-Arcis, Maria, et al.
Publicado: (2021)

Nanoparticle-antagomiR based targeting of miR-31 to induce osterix and osteocalcin expression in mesenchymal stem cells
por: McCully, Mark, et al.
Publicado: (2018)

Delivery of AntagomiR-7 through polymer nanoparticles for assisting B Cell to alleviate systemic lupus erythematosus
por: Guo, Hui, et al.
Publicado: (2023)

AntagomiR-451 inhibits oxygen glucose deprivation (OGD)-induced HUVEC necrosis via activating AMPK signaling
por: Yang, Xi, et al.
Publicado: (2017)

Modeling of Myotonic Dystrophy Cardiac Phenotypes in Drosophila
por: Chakraborty, Mouli, et al.
Publicado: (2018)

Six Serum miRNAs Fail to Validate as Myotonic Dystrophy Type 1 Biomarkers
por: Fernandez-Costa, Juan M., et al.
Publicado: (2016)

Enhanced effects of antagomiR-3074-3p-conjugated PEI-AuNPs on the odontogenic differentiation by targeting FKBP9
por: Jiang, Tao, et al.
Publicado: (2023)

Use of AgomiR and AntagomiR technologies to alter satellite cell proliferation in vitro, miRNA expression, and muscle fiber hypertrophy in intrauterine growth-restricted lambs
por: Greene, M. A., et al.
Publicado: (2023)

Delivery of antagomiR204-conjugated gold nanoparticles from PLGA sheets and its implication in promoting osseointegration of titanium implant in type 2 diabetes mellitus
por: Liu, Xiangwei, et al.
Publicado: (2017)

Targeting exosomes enveloped EBV‐miR‐BART1‐5p‐antagomiRs for NPC therapy through both anti‐vasculogenic mimicry and anti‐angiogenesis
por: Wang, Jianguo, et al.
Publicado: (2023)

Muscleblind, BSF and TBPH are mislocalized in the muscle sarcomere of a Drosophila myotonic dystrophy model
por: Llamusi, Beatriz, et al.
Publicado: (2013)

MicroRNA-Based Therapeutic Perspectives in Myotonic Dystrophy
por: López Castel, Arturo, et al.
Publicado: (2019)

Deciphering the Complex Molecular Pathogenesis of Myotonic Dystrophy Type 1 through Omics Studies
por: Espinosa-Espinosa, Jorge, et al.
Publicado: (2022)

Pentamidine rescues contractility and rhythmicity in a Drosophila model of myotonic dystrophy heart dysfunction
por: Chakraborty, Mouli, et al.
Publicado: (2015)

rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences
por: Sellier, Chantal, et al.
Publicado: (2018)

Targeting Myotonic Dystrophy Type 1 with Metformin
por: García-Puga, Mikel, et al.
Publicado: (2022)

In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models
por: González, Àlex L., et al.
Publicado: (2017)

Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy
por: Chakraborty, Mouli, et al.
Publicado: (2018)

CRISPR-Cas9 editing of a TNPO3 mutation in a muscle cell model of limb-girdle muscular dystrophy type D2
por: Poyatos-García, Javier, et al.
Publicado: (2023)

Defined d-hexapeptides bind CUG repeats and rescue phenotypes of myotonic dystrophy myotubes in a Drosophila model of the disease
por: Rapisarda, Anna, et al.
Publicado: (2021)

Antagomirbase- a putative antagomir database
por: Ganguli, Sayak, et al.
Publicado: (2011)

Social cognition in myotonic dystrophy type 1: Specific or secondary impairment?
por: Labayru, Garazi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_q98dn1kfv045hvk5l6i32e5kj3